Rockwell Medical, Inc. (DE) (RMTI) Dividend History

Company News

• DaVita Stock Gains 47.3% Year to Date: What's Behind the Rally?

  DaVita's stock has gained 47.3% year-to-date, outperforming the industry and the S&P 500. The rally is attributed to the company's strong dialysis and lab services, solid Q2 2024 performance, and expansion through acquisitions.

  Benzinga

  Featured Companies: DGX DVA RDNT
• Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates

  Rockwell Medical (RMTI) delivered earnings and revenue surprises of 60% and 7.06%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: ACB
• Returning To Rockwell Medical: Buy At 65% Of Revenue

  Rockwell Medical, a strong player in the hemodialysis market with a focus on cost-cutting and industry roll-up for improved financials. Read more on RMTI stock.

  Seeking Alpha
• 7 Cheap Penny Stocks to Buy According To Analysts, Targets Up To 1,090%

  Analysts say these are penny stocks to "buy" but do you agree? The post 7 Cheap Penny Stocks to Buy According To Analysts, Targets Up To 1,090% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: BLDE ORGO RIGL
• Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  WIXOM, Mich., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that a majority of the independent directors serving on the Company’s Board of Directors approved an option grant to a new employee to purchase 10,000 shares of the Company’s common stock (the “Inducement Grant”). The Inducement Grant has been granted outside of the Company’s Amended and Restated 2018 Long Term Incentive Plan (“Plan”), but remains subject to the terms and conditions of such Plan. The Inducement Grant was made as an inducement material to such individual entering into employment with Rockwell Medical in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grant has an exercise price of $0.40, which is equal to the closing price of Rockwell Medical’s common stock on February 10, 2022, the grant date of the award. The Inducement Grant will vest over a 3-year period, with one-third of the shares vesting on each of the first three anniversaries of the grant date, subject to continued employment through the applicable vesting dates.

  GlobeNewswire Inc.